REGN logo

REGN Cash From Investing

Annual CFI

-$2.47 B
+$717.00 M+22.51%

December 31, 2024


Summary


Performance

REGN Cash From Investing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherREGNcash flowmetrics:

Quarterly CFI

$350.60 M
+$925.00 M+161.04%

December 31, 2024


Summary


Performance

REGN Quarterly CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherREGNcash flowmetrics:

TTM CFI

-$2.47 B
+$416.80 M+14.45%

December 31, 2024


Summary


Performance

REGN TTM CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherREGNcash flowmetrics:

Cash From Investing Formula

CFI = Cash Inflows from Investments − Cash Outflows for Investments

REGN Cash From Investing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+22.5%+629.6%+22.5%
3 y3 years+54.2%+629.6%+22.5%
5 y5 years-21.7%+629.6%+22.5%

REGN Cash From Investing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+54.2%at high+114.7%-6.6%+62.4%
5 y5-year-3395.9%+54.2%-75.9%+114.4%-515.2%+62.4%
alltimeall time-2021.1%+54.2%-75.9%+114.4%-515.2%+62.4%

Regeneron Pharmaceuticals Cash From Investing History

DateAnnualQuarterlyTTM
Dec 2024
-$2.47 B(-22.5%)
$350.60 M(-161.0%)
-$2.47 B(-14.4%)
Sep 2024
-
-$574.40 M(+3.1%)
-$2.88 B(+2.8%)
Jun 2024
-
-$557.20 M(-67.0%)
-$2.81 B(-39.5%)
Mar 2024
-
-$1.69 B(+2448.5%)
-$4.64 B(+45.6%)
Dec 2023
-$3.19 B(-15.8%)
-$66.20 M(-86.7%)
-$3.19 B(-36.0%)
Sep 2023
-
-$496.30 M(-79.2%)
-$4.98 B(+16.1%)
Jun 2023
-
-$2.39 B(+912.7%)
-$4.29 B(+85.2%)
Mar 2023
-
-$235.70 M(-87.3%)
-$2.31 B(-38.8%)
Dec 2022
-$3.78 B(-29.7%)
-$1.86 B(-1066.0%)
-$3.78 B(-3.9%)
Sep 2022
-
$192.30 M(-146.5%)
-$3.94 B(-40.0%)
Jun 2022
-
-$413.90 M(-75.7%)
-$6.57 B(+8.9%)
Mar 2022
-
-$1.71 B(-15.3%)
-$6.03 B(+12.0%)
Dec 2021
-$5.38 B(+7527.1%)
-$2.01 B(-17.5%)
-$5.38 B(+46.4%)
Sep 2021
-
-$2.44 B(-2038.6%)
-$3.68 B(+82.6%)
Jun 2021
-
$125.80 M(-111.9%)
-$2.01 B(+193.4%)
Mar 2021
-
-$1.06 B(+247.2%)
-$686.40 M(+872.2%)
Dec 2020
-$70.60 M(-96.5%)
-$305.00 M(-60.7%)
-$70.60 M(-374.7%)
Sep 2020
-
-$775.80 M(-153.4%)
$25.70 M(-95.7%)
Jun 2020
-
$1.45 B(-427.9%)
$594.50 M(-135.1%)
Mar 2020
-
-$443.20 M(+112.4%)
-$1.69 B(-16.4%)
Dec 2019
-$2.03 B(+38.6%)
-$208.70 M(+0.8%)
-$2.03 B(-2.7%)
Sep 2019
-
-$207.00 M(-75.2%)
-$2.08 B(-3.7%)
Jun 2019
-
-$836.00 M(+7.7%)
-$2.16 B(+19.4%)
Mar 2019
-
-$776.10 M(+191.9%)
-$1.81 B(+24.0%)
Dec 2018
-$1.46 B(+45.5%)
-$265.90 M(-7.3%)
-$1.46 B(-4.6%)
Sep 2018
-
-$286.70 M(-40.9%)
-$1.53 B(-4.5%)
Jun 2018
-
-$485.00 M(+14.0%)
-$1.61 B(+24.4%)
Mar 2018
-
-$425.40 M(+26.7%)
-$1.29 B(+28.4%)
Dec 2017
-$1.01 B(-4.0%)
-$335.76 M(-6.4%)
-$1.01 B(+6.9%)
Sep 2017
-
-$358.88 M(+110.6%)
-$940.69 M(-4.8%)
Jun 2017
-
-$170.41 M(+21.6%)
-$987.66 M(-13.6%)
Mar 2017
-
-$140.14 M(-48.3%)
-$1.14 B(+9.2%)
Dec 2016
-$1.05 B(+15.3%)
-$271.25 M(-33.2%)
-$1.05 B(+16.5%)
Sep 2016
-
-$405.85 M(+24.5%)
-$898.85 M(+15.8%)
Jun 2016
-
-$326.01 M(+646.3%)
-$776.17 M(-5.6%)
Mar 2016
-
-$43.69 M(-64.6%)
-$821.80 M(-9.5%)
Dec 2015
-$907.60 M(+115.7%)
-$123.30 M(-56.5%)
-$907.60 M(+24.7%)
Sep 2015
-
-$283.17 M(-23.8%)
-$727.66 M(+28.2%)
Jun 2015
-
-$371.65 M(+187.0%)
-$567.55 M(+80.7%)
Mar 2015
-
-$129.48 M(-328.6%)
-$314.03 M(-25.4%)
Dec 2014
-$420.78 M(+18.4%)
$56.65 M(-146.0%)
-$420.78 M(-28.4%)
Sep 2014
-
-$123.07 M(+4.2%)
-$587.37 M(-13.5%)
Jun 2014
-
-$118.12 M(-50.0%)
-$678.75 M(+52.9%)
Mar 2014
-
-$236.23 M(+114.9%)
-$444.00 M(+24.9%)
Dec 2013
-$355.45 M(+338.4%)
-$109.95 M(-48.7%)
-$355.45 M(+130.2%)
Sep 2013
-
-$214.45 M(-283.9%)
-$154.40 M(-1467.1%)
Jun 2013
-
$116.63 M(-179.0%)
$11.29 M(-104.6%)
Mar 2013
-
-$147.69 M(-262.1%)
-$244.52 M(+201.6%)
Dec 2012
-$81.07 M(-163.1%)
$91.10 M(-286.9%)
-$81.07 M(-60.7%)
Sep 2012
-
-$48.75 M(-65.0%)
-$206.08 M(+30.2%)
Jun 2012
-
-$139.19 M(-982.8%)
-$158.23 M(-227.7%)
Mar 2012
-
$15.77 M(-146.5%)
$123.89 M(-3.6%)
Dec 2011
$128.47 M(-129.4%)
-$33.91 M(+3655.0%)
$128.47 M(-166.8%)
Sep 2011
-
-$903.00 K(-100.6%)
-$192.24 M(+36.2%)
Jun 2011
-
$142.94 M(+602.5%)
-$141.17 M(-49.6%)
Mar 2011
-
$20.35 M(-105.7%)
-$280.28 M(-35.9%)
Dec 2010
-$437.03 M(<-9900.0%)
-$354.62 M(-806.8%)
-$437.03 M(+330.2%)
Sep 2010
-
$50.17 M(+1213.4%)
-$101.58 M(-38.5%)
Jun 2010
-
$3.82 M(-102.8%)
-$165.22 M(+70.8%)
Mar 2010
-
-$136.40 M(+611.5%)
-$96.72 M(<-9900.0%)
Dec 2009
$146.00 K(-99.5%)
-$19.17 M(+42.3%)
$146.00 K(-99.9%)
Sep 2009
-
-$13.47 M(-118.6%)
$103.99 M(-42.3%)
Jun 2009
-
$72.33 M(-282.9%)
$180.24 M(-486.2%)
Mar 2009
-
-$39.54 M(-146.7%)
-$46.67 M(-251.4%)
Dec 2008
$30.82 M
$84.67 M(+34.9%)
$30.82 M(-277.2%)
Sep 2008
-
$62.78 M(-140.6%)
-$17.39 M(-78.8%)
DateAnnualQuarterlyTTM
Jun 2008
-
-$154.58 M(-507.4%)
-$82.04 M(-411.6%)
Mar 2008
-
$37.94 M(+4.1%)
$26.33 M(-130.7%)
Dec 2007
-$85.72 M(-44.7%)
$36.46 M(-2045.7%)
-$85.72 M(-70.0%)
Sep 2007
-
-$1.87 M(-95.9%)
-$285.40 M(+31.5%)
Jun 2007
-
-$46.20 M(-37.7%)
-$217.06 M(-0.6%)
Mar 2007
-
-$74.11 M(-54.6%)
-$218.35 M(+40.8%)
Dec 2006
-$155.10 M(-234.3%)
-$163.21 M(-345.6%)
-$155.10 M(-564.2%)
Sep 2006
-
$66.46 M(-240.0%)
$33.41 M(+162.1%)
Jun 2006
-
-$47.48 M(+336.8%)
$12.75 M(-85.2%)
Mar 2006
-
-$10.87 M(-143.0%)
$86.20 M(-25.4%)
Dec 2005
$115.49 M(-2620.1%)
$25.30 M(-44.8%)
$115.49 M(+27.8%)
Sep 2005
-
$45.80 M(+76.4%)
$90.35 M(+134.3%)
Jun 2005
-
$25.97 M(+40.9%)
$38.57 M(-164.9%)
Mar 2005
-
$18.43 M(>+9900.0%)
-$59.39 M(+1195.9%)
Dec 2004
-$4.58 M(-92.8%)
$163.00 K(-102.7%)
-$4.58 M(-97.2%)
Sep 2004
-
-$5.99 M(-91.7%)
-$161.24 M(+65.2%)
Jun 2004
-
-$71.99 M(-198.3%)
-$97.62 M(+86.2%)
Mar 2004
-
$73.23 M(-146.8%)
-$52.43 M(-17.9%)
Dec 2003
-$63.84 M(+9.1%)
-$156.49 M(-371.6%)
-$63.84 M(-150.0%)
Sep 2003
-
$57.63 M(-315.1%)
$127.58 M(+27.5%)
Jun 2003
-
-$26.80 M(-143.3%)
$100.06 M(+10.9%)
Mar 2003
-
$61.82 M(+77.0%)
$90.23 M(-254.2%)
Dec 2002
-$58.52 M(-22.4%)
$34.94 M(+16.1%)
-$58.52 M(-51.1%)
Sep 2002
-
$30.10 M(-182.2%)
-$119.66 M(-30.1%)
Jun 2002
-
-$36.63 M(-57.9%)
-$171.25 M(+1.2%)
Mar 2002
-
-$86.93 M(+231.7%)
-$169.20 M(+124.4%)
Dec 2001
-$75.39 M(+30.7%)
-$26.21 M(+22.0%)
-$75.39 M(+18.0%)
Sep 2001
-
-$21.49 M(-37.9%)
-$63.91 M(-27.5%)
Jun 2001
-
-$34.58 M(-602.1%)
-$88.10 M(+65.3%)
Mar 2001
-
$6.89 M(-146.7%)
-$53.30 M(-7.6%)
Dec 2000
-$57.68 M(-437.3%)
-$14.73 M(-67.7%)
-$57.68 M(+14.8%)
Sep 2000
-
-$45.68 M(<-9900.0%)
-$50.24 M(-905.8%)
Jun 2000
-
$226.00 K(-91.0%)
$6.24 M(-36.4%)
Mar 2000
-
$2.51 M(-134.4%)
$9.81 M(-42.6%)
Dec 1999
$17.10 M(+584.0%)
-$7.30 M(-167.6%)
$17.10 M(-38.0%)
Sep 1999
-
$10.80 M(+184.2%)
$27.60 M(+112.3%)
Jun 1999
-
$3.80 M(-61.2%)
$13.00 M(-24.9%)
Mar 1999
-
$9.80 M(+206.3%)
$17.30 M(+592.0%)
Dec 1998
$2.50 M(-106.4%)
$3.20 M(-184.2%)
$2.50 M(-117.7%)
Sep 1998
-
-$3.80 M(-146.9%)
-$14.10 M(-26.2%)
Jun 1998
-
$8.10 M(-262.0%)
-$19.10 M(-54.2%)
Mar 1998
-
-$5.00 M(-62.7%)
-$41.70 M(+7.2%)
Dec 1997
-$38.90 M(-12.2%)
-$13.40 M(+52.3%)
-$38.90 M(+2.6%)
Sep 1997
-
-$8.80 M(-39.3%)
-$37.90 M(+16.3%)
Jun 1997
-
-$14.50 M(+559.1%)
-$32.60 M(-0.6%)
Mar 1997
-
-$2.20 M(-82.3%)
-$32.80 M(-26.0%)
Dec 1996
-$44.30 M(-698.6%)
-$12.40 M(+254.3%)
-$44.30 M(+53.3%)
Sep 1996
-
-$3.50 M(-76.2%)
-$28.90 M(+18.4%)
Jun 1996
-
-$14.70 M(+7.3%)
-$24.40 M(+916.7%)
Mar 1996
-
-$13.70 M(-556.7%)
-$2.40 M(-132.4%)
Dec 1995
$7.40 M(-76.8%)
$3.00 M(+200.0%)
$7.40 M(-67.5%)
Sep 1995
-
$1.00 M(-86.3%)
$22.80 M(-10.6%)
Jun 1995
-
$7.30 M(-287.2%)
$25.50 M(+8.1%)
Mar 1995
-
-$3.90 M(-121.2%)
$23.60 M(-26.0%)
Dec 1994
$31.90 M(-235.2%)
$18.40 M(+397.3%)
$31.90 M(-878.0%)
Sep 1994
-
$3.70 M(-31.5%)
-$4.10 M(-80.4%)
Jun 1994
-
$5.40 M(+22.7%)
-$20.90 M(+2.0%)
Mar 1994
-
$4.40 M(-125.0%)
-$20.50 M(-13.1%)
Dec 1993
-$23.60 M(-387.8%)
-$17.60 M(+34.4%)
-$23.60 M(+807.7%)
Sep 1993
-
-$13.10 M(-325.9%)
-$2.60 M(-122.2%)
Jun 1993
-
$5.80 M(+346.2%)
$11.70 M(+56.0%)
Mar 1993
-
$1.30 M(-61.8%)
$7.50 M(-8.5%)
Dec 1992
$8.20 M(-110.6%)
$3.40 M(+183.3%)
$8.20 M(+70.8%)
Sep 1992
-
$1.20 M(-25.0%)
$4.80 M(+33.3%)
Jun 1992
-
$1.60 M(-20.0%)
$3.60 M(+80.0%)
Mar 1992
-
$2.00 M
$2.00 M
Dec 1991
-$77.60 M
-
-

FAQ

  • What is Regeneron Pharmaceuticals annual cash flow from investing activities?
  • What is the all time high annual CFI for Regeneron Pharmaceuticals?
  • What is Regeneron Pharmaceuticals annual CFI year-on-year change?
  • What is Regeneron Pharmaceuticals quarterly cash flow from investing activities?
  • What is the all time high quarterly CFI for Regeneron Pharmaceuticals?
  • What is Regeneron Pharmaceuticals quarterly CFI year-on-year change?
  • What is Regeneron Pharmaceuticals TTM cash flow from investing activities?
  • What is the all time high TTM CFI for Regeneron Pharmaceuticals?
  • What is Regeneron Pharmaceuticals TTM CFI year-on-year change?

What is Regeneron Pharmaceuticals annual cash flow from investing activities?

The current annual CFI of REGN is -$2.47 B

What is the all time high annual CFI for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals all-time high annual cash flow from investing activities is $128.47 M

What is Regeneron Pharmaceuticals annual CFI year-on-year change?

Over the past year, REGN annual cash flow from investing activities has changed by +$717.00 M (+22.51%)

What is Regeneron Pharmaceuticals quarterly cash flow from investing activities?

The current quarterly CFI of REGN is $350.60 M

What is the all time high quarterly CFI for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals all-time high quarterly cash flow from investing activities is $1.45 B

What is Regeneron Pharmaceuticals quarterly CFI year-on-year change?

Over the past year, REGN quarterly cash flow from investing activities has changed by +$416.80 M (+629.61%)

What is Regeneron Pharmaceuticals TTM cash flow from investing activities?

The current TTM CFI of REGN is -$2.47 B

What is the all time high TTM CFI for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals all-time high TTM cash flow from investing activities is $594.50 M

What is Regeneron Pharmaceuticals TTM CFI year-on-year change?

Over the past year, REGN TTM cash flow from investing activities has changed by +$717.00 M (+22.51%)